Kanuma for the treatment of lysosomal acid lipase deficiency in the EU and Strensiq as long-term enzyme replacement therapy in patients with pediatric-onset hypophosphatasia to treat the bone manifestations of the disease in the U.S. and EU was approved recently.
Alexion has a mixed earnings track record with the company delivering positive earnings surprises in one of the last four quarters.
Currently, Alexion has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion’s earnings beats expectations. Our consensus called for EPS of 78 cents, and the company reported EPS of 96 cents (these figures include stock-based compensation expense).
Revenue: Revenues were slightly below expectations. Alexion posted revenues of $666.6 million, compared to our consensus estimate of $668 million.
Key Stats: Soliris continues to drive revenues at Alexion. The company revised it’s 2015 outlook. The company expects adjusted earnings per share in the range of $4.92 to $4.97 per share in 2015 as compared to previous guidance of $4.70 to $4.80 per share.
The company revised its revenue guidance to reflect the impact of macroeconomic factors in Latin American countries. The company expects revenues in the lower end of the previously guided range of $2.6–$2.62 billion. Foreign exchange translations are expected to negatively impact revenues by 6%.